Revolution Medicines, Inc.
RVMD
Rank in Stocks
#619
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Share Price
$187.63
Market Cap
$40.22B
Change (1 day)
3.01%
Change (1 year)
247.40%
Country
US
Trade Revolution Medicines, Inc. (RVMD)
Category
Healthcare
P/E ratio for Revolution Medicines, Inc. (RVMD)
P/E ratio as of October 2026 TTM: -21.84
According to Revolution Medicines, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.84. At the end of 2023 the company had a P/E ratio of -7.44.
P/E ratio history for Revolution Medicines, Inc. from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -21.84 | 78.59% |
| 2024 | -12.23 | 64.40% |
| 2023 | -7.44 | -3.70% |
| 2022 | -7.72 | -21.16% |
| 2021 | -9.79 | -59.82% |
| 2020 | -24.38 | 10.23% |
| 2019 | -22.11 | -12.33% |
| 2018 | -25.22 | -25.51% |
| 2017 | -33.86 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -231.77% |
US
|
|
| -28.36 | 29.83% |
US
|
|
| -24.57 | 12.48% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -238.86% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.